+86-28-82633987
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
290.4300
2.1901
.2568
.0596
.7410
.8099
Low
89.3584
5.1453
Yes
No
No
No
No
No
0.6
Yes
No
Yes
No
Thonningianin B (CAS No.: 271579-12-5), as a natural product, has attracted significant attention in recent years due to its significant antioxidant and autophagy-enhancing activities. Natural products have unique advantages in drug development, especially in the prevention and treatment of liver diseases, becoming a research hotspot due to their multi-target regulation and low side effects. As an important metabolic and detoxifying organ in the human body, the liver is easily affected by various pathological factors such as oxidative stress, inflammation, and fibrosis, which can lead to liver damage and even serious diseases like cirrhosis and liver cancer. Ganxangpi glycoside B demonstrates excellent liver-protective potential by regulating various antioxidant enzymes and signaling pathways, making it an emerging candidate molecule for natural drug development.
This paper aims to systematically review the chemical structure and physicochemical properties of Ganhuangpiao glycoside B, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics. Combined with the latest research progress, it explores its clinical application prospects and future directions, providing theoretical support and research reference for the pharmacology of natural products and liver disease treatment.
Ganhuangti glycoside B is a natural phenolic glycoside compound with a molecular weight of 722.6080, featuring a complex molecular formula and containing multiple phenolic hydroxyl groups and glycoside structural units. Its LogP value is 2.1901, indicating moderate lipid solubility, which is beneficial for cell membrane penetration and bioavailability. TPSA (Topological Polar Surface Area) reached as high as 290.43, indicating strong molecular polarity, which may affect transmembrane transport and oral absorption. Low water solubility (0.0596 mg/mL) suggests limited solubility in aqueous media, and bioavailability should be improved through appropriate formulation techniques.
Structurally, Ganhuangti glycoside B contains multiple phenolic hydroxyl groups and glycosidic bonds, giving it excellent antioxidant activity and ability to bind to protein targets. Its low blood-brain barrier permeability reduces the risk of central nervous system side effects. The negative hERG channel inhibition and Ames test results (0.6) indicate a low genotoxicity risk and good safety.
Ganhuangqu glycoside B is mainly found in plants of the genus Ganhuang, especially in high levels in traditional Chinese medicinal materials such as Thonningia sanguinea. As a traditional African herb, ganhuangcao is widely used to treat inflammation, infections, and liver diseases. Its rhizomes and whole herbs are the main medicinal parts and contain abundant phenolic glycoside compounds.
The extraction process typically uses ethanol or methanol as solvent, and crude extracts are obtained through cold immersion, reflux extraction, or ultrasonic-assisted extraction. Subsequently, techniques such as liquid-liquid partitioning, column chromatography (silica gel, C18 reversed), and high-performance liquid chromatography (HPLC) were used for separation and purification, ultimately obtaining high-purity xanthoxytriol B. Modern extraction technologies such as supercritical fluid extraction and membrane separation are gradually being applied to extract this compound, improving extraction efficiency and purity.
As a natural antioxidant, Fentinoside B can eliminate free radicals and reduce oxidative stress damage. In vitro studies have shown that it has significant DPPH radical scavenging ability and superoxide anion scavenging activity. In vivo experiments, basticonin B significantly enhances antioxidant enzyme activity in liver tissue, such as SOD1, SOD2, CAT, and GPX1, reduces levels of lipid peroxidation products (such as MDA), and alleviates oxidative damage to hepatocytes.
Autophagy, as an important intracellular metabolic regulatory mechanism, participates in organelle renewal and stress responses. Xanthazin B can promote the expression of autophagy-related protein LC3-II, enhance autophagy flow, and facilitate the clearance of damaged organelles and proteins, thereby protecting hepatocytes from toxic damage. This effect helps maintain liver cell homeostasis and delays the progression of liver fibrosis.
Multiple in vivo liver injury models (such as CCl4-induced liver fibrosis and alcoholic liver injury) have shown that baitazin B can significantly reduce serum transaminase (ALT, AST) levels, alleviating liver tissue inflammation and fibrosis pathological changes. Its mechanism of action involves multiple pathways, including antioxidant, anti-inflammatory, regulation of apoptosis, and autophagy.
The hepatoprotective effect of basinin B is closely related to its regulation of several key molecular targets:
NRF2 (Nuclear Factor 2-Related Factor 2): As the main regulator of cellular antioxidant responses, NRF2 activates to promote the expression of downstream antioxidant enzymes (NQO1, HMOX1, SOD1, CAT, GPX1, etc.), enhancing cellular antioxidant capacity. Huangti glycoside B can promote NRF2 nuclear translocation, activate its signaling pathway, and alleviate oxidative stress.
MMP9 (matrix metalloproteinase 9): MMP9 mediates the degradation and remodeling of the extracellular matrix during liver fibrosis. Ganxanthon B regulates MMP9 expression, inhibits excessive matrix deposition, and alleviates liver fibrosis.
TGFB1 (Transforming Growth Factor β1): TGFB1 is the core pro-fibrotic factor for liver fibrosis. Huangti glycoside B can inhibit the TGFB1 signaling pathway, block hepatic stellate cell activation, and slow the progression of fibrosis.
ACTA2 (α-smooth muscle actin): As a marker of hepatic stellate cell activation, reduced ACTA2 expression reflects fibrotic inhibition. Ganxanthon B can reduce ACTA2 expression and inhibit liver fibrosis.
In addition, Ganxangquatin B exerts hepatoprotective effects by regulating mitochondrial function, inhibiting the release of inflammatory factors, and promoting autophagy, demonstrating its multi-target and multi-pathway pharmacological characteristics.
Huangti glycoside B has high molecular weight and polarity, and a high TPSA value, suggesting that oral absorption may be limited and that bioavailability should be improved through formulation optimization. The LogP is moderate, which promotes cell membrane permeability, but its water solubility is relatively low, which may affect distribution and absorption rates in the body.
Low blood-brain barrier permeability reduces the risk of central nervous system toxicity. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. Ames trial results showed that it carries a low genotoxicity risk and is safe.
Currently, pharmacokinetic studies on Fenhetiduin B are limited. Preliminary data indicate that its metabolism is stable in the body, mainly processed by hepatic metabolic enzyme systems, and excreted mainly through bile and urine. In the future, further systematic pharmacokinetic and toxicological studies are needed to clarify its in vivo kinetic characteristics and safe dosage range.
As a natural antioxidant and autophagy enhancer, xanthonin B shows broad application prospects in liver disease prevention and treatment. Its multi-target regulatory capability makes it suitable not only for protecting liver injury but also potentially extending to liver fibrosis, non-alcoholic fatty liver disease (NAFLD), drug-induced liver injury, and other liver disease fields.
Future research directions include:
Formulation Development: To address its poor water solubility and limited oral absorption, new delivery systems such as nanoformulations, liposomes, or solid dispersions are being developed to improve bioavailability and targeting.
In-depth mechanism analysis: Using multi-omics techniques such as genomics and proteomics, the molecular network of Fenxangi-Glycoside B regulating autophagy, oxidative stress, and fibrosis is further revealed.
Preclinical and clinical research: Conduct systematic pharmacokinetics, toxicology evaluations, and multicenter clinical trials to verify safety and efficacy, and promote clinical translation.
Combination and Combination Medication: Explore the synergistic effects of Gxantzonin B with other natural products or Western medicines to optimize treatment plans and enhance efficacy.
In summary, as a promising natural drug molecule, Ganxinin B has the foundation and conditions to become a new drug for treating liver diseases.
As a natural product, Ganxangpi glycoside B demonstrates unique advantages in liver protection due to its remarkable antioxidant and autophagy-enhancing activities. Its multi-target and multi-mechanism mode of action offers new ideas for comprehensive treatment of liver diseases. Although its pharmacokinetics and clinical research are still in the early stages, with continuous improvements in extraction and purification technology, drug design, and clinical evaluation systems, Ganhuangquatin B is expected to become an important candidate drug in the prevention and treatment of liver diseases.
In the future, efforts should be made to integrate basic and clinical research, promote systematic development and application of Ganhuang Glycoside B, fully leverage the value of natural products in modern medicine, and provide new treatment options for liver disease patients.
Shenshuai
Wenjing
Hedandan
